WEREWOLF THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Increase Decrease In Operating Lease Liability of -$3.38 million for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$2.77M.
- WEREWOLF THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$615.00K.
- WEREWOLF THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$209.00K.
- WEREWOLF THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$397.00K.
- WEREWOLF THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$2.08M.
- WEREWOLF THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$977.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.77M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | -$3.38M S-4 · filed 2026-09-22 | -$3.59M derived: sum of 3 quarters · filed 2026-09-22 | -$3.99M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | -$615.00K 10-Q · filed 2026-05-07 | -$824.00K derived: sum of 2 quarters · filed 2026-09-22 | -$1.22M derived: sum of 3 quarters · filed 2026-09-22 | -$1.61M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | -$209.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | -$606.00K derived: sum of 2 quarters · filed 2026-09-22 | -$994.00K derived: sum of 3 quarters · filed 2026-09-22 | -$1.56M S-4 · filed 2026-09-22 |
| 2025-09-30 | -$397.00K derived: 10-Q 9 month − S-4 6 month · filed 2025-11-04 | -$785.00K derived: sum of 2 quarters · filed 2026-09-22 | -$1.35M 10-Q · filed 2025-11-04 | -$1.52M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | -$388.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | -$951.00K S-4 · filed 2026-09-22 | -$1.12M derived: sum of 3 quarters · filed 2026-09-22 | -$1.47M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | -$563.00K 10-Q · filed 2026-05-07 | -$732.00K derived: sum of 2 quarters · filed 2026-09-22 | -$1.08M derived: sum of 3 quarters · filed 2026-09-22 | -$1.43M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | -$169.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | -$521.00K derived: sum of 2 quarters · filed 2026-09-22 | -$864.00K derived: sum of 3 quarters · filed 2026-09-22 | -$1.61M S-4 · filed 2026-09-22 |
| 2024-09-30 | -$352.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$695.00K derived: sum of 2 quarters · filed 2025-11-04 | -$1.44M 10-Q · filed 2025-11-04 | -$1.80M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$343.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.09M 10-Q · filed 2025-08-14 | -$1.44M derived: sum of 3 quarters · filed 2025-08-14 | -$2.16M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$744.00K 10-Q · filed 2025-05-08 | -$1.10M derived: sum of 2 quarters · filed 2025-05-08 | -$1.82M derived: sum of 3 quarters · filed 2025-05-08 | -$2.33M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$1.07M derived: sum of 2 quarters · filed 2025-03-11 | -$1.59M derived: sum of 3 quarters · filed 2025-03-11 | -$2.08M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$718.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.23M derived: sum of 2 quarters · filed 2024-11-07 | -$1.73M 10-Q · filed 2024-11-07 | -$2.21M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$514.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.01M 10-Q · filed 2024-08-08 | -$1.49M derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$495.00K 10-Q · filed 2024-05-03 | -$974.00K derived: sum of 2 quarters · filed 2024-05-03 | ||
| 2022-12-31 | -$479.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$977.00K 10-K · filed 2024-03-07 | ||
| 2022-09-30 | -$498.00K 10-Q · filed 2023-11-14 | |||
| 2021-03-31 | -$159.00K 10-Q · filed 2021-06-10 | |||
| 2020-03-31 | -$71.00K 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |